BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30282693)

  • 1. p95HER2-T cell bispecific antibody for breast cancer treatment.
    Rius Ruiz I; Vicario R; Morancho B; Morales CB; Arenas EJ; Herter S; Freimoser-Grundschober A; Somandin J; Sam J; Ast O; Barriocanal ÁM; Luque A; Escorihuela M; Varela I; Cuartas I; Nuciforo P; Fasani R; Peg V; Rubio I; Cortés J; Serra V; Escriva-de-Romani S; Sperinde J; Chenna A; Huang W; Winslow J; Albanell J; Seoane J; Scaltriti M; Baselga J; Tabernero J; Umana P; Bacac M; Saura C; Klein C; Arribas J
    Sci Transl Med; 2018 Oct; 10(461):. PubMed ID: 30282693
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel asymmetrical anti-HER2/CD3 bispecific antibody exhibits potent cytotoxicity for HER2-positive tumor cells.
    Yu S; Zhang J; Yan Y; Yao X; Fang L; Xiong H; Liu Y; Chu Q; Zhou P; Wu K
    J Exp Clin Cancer Res; 2019 Aug; 38(1):355. PubMed ID: 31412896
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer.
    Scaltriti M; Rojo F; Ocaña A; Anido J; Guzman M; Cortes J; Di Cosimo S; Matias-Guiu X; Ramon y Cajal S; Arribas J; Baselga J
    J Natl Cancer Inst; 2007 Apr; 99(8):628-38. PubMed ID: 17440164
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Construction and evaluation of a novel humanized HER2-specific chimeric receptor.
    Sun M; Shi H; Liu C; Liu J; Liu X; Sun Y
    Breast Cancer Res; 2014 Jun; 16(3):R61. PubMed ID: 24919843
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Quantitation of p95HER2 in paraffin sections by using a p95-specific antibody and correlation with outcome in a cohort of trastuzumab-treated breast cancer patients.
    Sperinde J; Jin X; Banerjee J; Penuel E; Saha A; Diedrich G; Huang W; Leitzel K; Weidler J; Ali SM; Fuchs EM; Singer CF; Köstler WJ; Bates M; Parry G; Winslow J; Lipton A
    Clin Cancer Res; 2010 Aug; 16(16):4226-35. PubMed ID: 20664024
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiformat T-cell-engaging bispecific antibodies targeting human breast cancers.
    Cao Y; Axup JY; Ma JS; Wang RE; Choi S; Tardif V; Lim RK; Pugh HM; Lawson BR; Welzel G; Kazane SA; Sun Y; Tian F; Srinagesh S; Javahishvili T; Schultz PG; Kim CH
    Angew Chem Int Ed Engl; 2015 Jun; 54(24):7022-7. PubMed ID: 25919418
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Protease-activation using anti-idiotypic masks enables tumor specificity of a folate receptor 1-T cell bispecific antibody.
    Geiger M; Stubenrauch KG; Sam J; Richter WF; Jordan G; Eckmann J; Hage C; Nicolini V; Freimoser-Grundschober A; Ritter M; Lauer ME; Stahlberg H; Ringler P; Patel J; Sullivan E; Grau-Richards S; Endres S; Kobold S; Umaña P; Brünker P; Klein C
    Nat Commun; 2020 Jun; 11(1):3196. PubMed ID: 32581215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor.
    Scaltriti M; Chandarlapaty S; Prudkin L; Aura C; Jimenez J; Angelini PD; Sánchez G; Guzman M; Parra JL; Ellis C; Gagnon R; Koehler M; Gomez H; Geyer C; Cameron D; Arribas J; Rosen N; Baselga J
    Clin Cancer Res; 2010 May; 16(9):2688-95. PubMed ID: 20406840
    [TBL] [Abstract][Full Text] [Related]  

  • 9. IFNγ-induced Chemokines Are Required for CXCR3-mediated T-Cell Recruitment and Antitumor Efficacy of Anti-HER2/CD3 Bispecific Antibody.
    Li J; Ybarra R; Mak J; Herault A; De Almeida P; Arrazate A; Ziai J; Totpal K; Junttila MR; Walsh KB; Junttila TT
    Clin Cancer Res; 2018 Dec; 24(24):6447-6458. PubMed ID: 29950350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors.
    Bacac M; Fauti T; Sam J; Colombetti S; Weinzierl T; Ouaret D; Bodmer W; Lehmann S; Hofer T; Hosse RJ; Moessner E; Ast O; Bruenker P; Grau-Richards S; Schaller T; Seidl A; Gerdes C; Perro M; Nicolini V; Steinhoff N; Dudal S; Neumann S; von Hirschheydt T; Jaeger C; Saro J; Karanikas V; Klein C; Umaña P
    Clin Cancer Res; 2016 Jul; 22(13):3286-97. PubMed ID: 26861458
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumor efficacy of a bispecific antibody that targets HER2 and activates T cells.
    Junttila TT; Li J; Johnston J; Hristopoulos M; Clark R; Ellerman D; Wang BE; Li Y; Mathieu M; Li G; Young J; Luis E; Lewis Phillips G; Stefanich E; Spiess C; Polson A; Irving B; Scheer JM; Junttila MR; Dennis MS; Kelley R; Totpal K; Ebens A
    Cancer Res; 2014 Oct; 74(19):5561-71. PubMed ID: 25228655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A T-cell-engaging B7-H4/CD3-bispecific Fab-scFv Antibody Targets Human Breast Cancer.
    Iizuka A; Nonomura C; Ashizawa T; Kondou R; Ohshima K; Sugino T; Mitsuya K; Hayashi N; Nakasu Y; Maruyama K; Yamaguchi K; Akiyama Y
    Clin Cancer Res; 2019 May; 25(9):2925-2934. PubMed ID: 30737243
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy.
    Parra-Palau JL; Morancho B; Peg V; Escorihuela M; Scaltriti M; Vicario R; Zacarias-Fluck M; Pedersen K; Pandiella A; Nuciforo P; Serra V; Cortés J; Baselga J; Perou CM; Prat A; Rubio IT; Arribas J
    J Natl Cancer Inst; 2014 Nov; 106(11):. PubMed ID: 25253614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-CD3 x anti-HER2 bispecific antibody effectively redirects armed T cells to inhibit tumor development and growth in hormone-refractory prostate cancer-bearing severe combined immunodeficient beige mice.
    Davol PA; Smith JA; Kouttab N; Elfenbein GJ; Lum LG
    Clin Prostate Cancer; 2004 Sep; 3(2):112-21. PubMed ID: 15479495
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fully human HER2/cluster of differentiation 3 bispecific antibody triggers potent and specific cytotoxicity of T lymphocytes against breast cancer.
    Zhou Y; Gou LT; Guo ZH; Liu HR; Wang JM; Zhou SX; Yang JL; Li XA
    Mol Med Rep; 2015 Jul; 12(1):147-54. PubMed ID: 25760691
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bispecific HER2 x CD3 antibodies enhance T-cell cytotoxicity in vitro and localize to HER2-overexpressing xenografts in nude mice.
    Shalaby MR; Carter P; Maneval D; Giltinan D; Kotts C
    Clin Immunol Immunopathol; 1995 Feb; 74(2):185-92. PubMed ID: 7828373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Relative Target Affinities of T-Cell-Dependent Bispecific Antibodies Determine Biodistribution in a Solid Tumor Mouse Model.
    Mandikian D; Takahashi N; Lo AA; Li J; Eastham-Anderson J; Slaga D; Ho J; Hristopoulos M; Clark R; Totpal K; Lin K; Joseph SB; Dennis MS; Prabhu S; Junttila TT; Boswell CA
    Mol Cancer Ther; 2018 Apr; 17(4):776-785. PubMed ID: 29339550
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A novel bispecific antibody targeting CD3 and prolactin receptor (PRLR) against PRLR-expression breast cancer.
    Zhou Y; Zong H; Han L; Xie Y; Jiang H; Gilly J; Zhang B; Lu H; Chen J; Sun R; Pan Z; Zhu J
    J Exp Clin Cancer Res; 2020 May; 39(1):87. PubMed ID: 32398042
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2 as a promising target for cytotoxicity T cells in human melanoma therapy.
    Ma J; Han H; Liu D; Li W; Feng H; Xue X; Wu X; Niu G; Zhang G; Zhao Y; Liu C; Tao H; Gao B
    PLoS One; 2013; 8(8):e73261. PubMed ID: 24015299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of anti-CD3 x anti-HER2/neu bispecific antibody for redirecting cytotoxicity of activated T cells toward HER2/neu+ tumors.
    Sen M; Wankowski DM; Garlie NK; Siebenlist RE; Van Epps D; LeFever AV; Lum LG
    J Hematother Stem Cell Res; 2001 Apr; 10(2):247-60. PubMed ID: 11359672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.